Core Insights - Artios Pharma Limited has appointed three senior leaders to enhance its late-stage development capabilities and prepare for commercial readiness, including Roy W. Ware as Chief Manufacturing and Technology Officer, Caryn Barnett as Vice President of Clinical Operations, and Pablo Lee as Vice President of Medical Affairs [1][6] Group 1: Leadership Appointments - Roy W. Ware, PhD, MBA, brings over 20 years of experience in CMC strategy, manufacturing, and global supply chain leadership, previously serving at Chimerix where he oversaw FDA submissions for Tembexa® and Modeyso® [3] - Caryn Barnett has over 30 years of experience in biopharmaceuticals, having led late-phase oncology programs through registration and approval, including Cyramza® and Verzenio® [4] - Pablo Lee, MD, MBA, has more than 25 years of experience in medical practice and global medical affairs, previously involved in the launch planning of Modeyso® and has held senior roles at Eli Lilly [5] Group 2: Company Focus and Pipeline - Artios Pharma is focused on developing new classes of medicines that target DNA Damage Response (DDR) pathways, with a mission to deliver meaningful survival benefits for cancer patients [7] - The company is advancing its lead program, alnodesertib, into late-stage development and potential commercialization in the U.S., while also executing a Phase 2 study for ART6043 [1][2]